Targeting enabled homolog with daunorubicin inhibits ERK1/2/c-Fos pathway and suppresses hepatocellular carcinoma progression

Zhi-Mei Li; Guan Liu; Qing-Qing Liu; Wei-Ming You; Ming-Gao Zhao

doi:10.1002/ctm2.70366

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (6) : e70366 DOI: 10.1002/ctm2.70366

LETTER TO THE JOURNAL

Targeting enabled homolog with daunorubicin inhibits ERK1/2/c-Fos pathway and suppresses hepatocellular carcinoma progression

Author information +

History +

PDF

Cite this article

Download citation ▾

Zhi-Mei Li, Guan Liu, Qing-Qing Liu, Wei-Ming You, Ming-Gao Zhao. Targeting enabled homolog with daunorubicin inhibits ERK1/2/c-Fos pathway and suppresses hepatocellular carcinoma progression. Clinical and Translational Medicine, 2025, 15(6): e70366 DOI:10.1002/ctm2.70366

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Deng G, Luo Y, Zhang Y, et al. Enabled homolog (ENAH) regulated by RNA binding protein splicing factor 3b subunit 4 (SF3B4) exacerbates the proliferation, invasion and migration of hepatocellular carcinoma cells via Notch signaling pathway. Bioengineered. 2022; 13: 2194-2206.

[2]	Opitz R, Muller M, Reuter C, et al. A modular toolkit to inhibit proline-rich motif-mediated protein-protein interactions. Proc Natl Acad Sci U S A. 2015; 112: 5011-5016.

[3]	Gui J, Zhou H, Wan H, et al. The role of vasodilator-stimulated phosphoproteins in the development of malignant tumors. Curr Cancer Drug Targets. 2024; 24: 477-489.

[4]	Melchionna R, Spada S, Di Modugno F, et al. The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation. EMBO Rep. 2020; 21: e50078.

[5]	Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 1998; 27: 951-958.

[6]	Zhang H, Xu Z, Xu Z, et al. The development of alpha, beta-unsaturated lactam-based andrographolide derivatives as anti-gastric cancer agents with the ability of inhibiting the ERK/c-Fos/Jun pathway. Eur J Med Chem. 2025; 286: 117291.

[7]	Di Modugno F, DeMonte L, Balsamo M, et al. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. Cancer Res. 2007; 67: 2657-2665.

[8]	Han C, He S, Wang R, et al. The role of ARHGAP9: clinical implication and potential function in acute myeloid leukemia. J Transl Med. 2021; 19: 65.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.